IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.

MLA

Tagliaferri, Annarita, et al. “IDEAL Study: A Real-World Assessment of Pattern of Use and Clinical Outcomes with Recombinant Coagulation Factor IX Albumin Fusion Protein (RIX-FP) in Patients with Haemophilia B in Italy.” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 29, no. 1, Jan. 2023, pp. 135–44. EBSCOhost, https://doi.org/10.1111/hae.14689.

APA

Tagliaferri, A., Molinari, A. C., Peyvandi, F., Coppola, A., Demartis, F., Biasoli, C., Borchiellini, A., Cultrera, D., De Cristofaro, R., Daniele, F., Giordano, P., Marchesini, E., Margaglione, M., Marino, R., Pollio, B., Radossi, P., Santoro, C., Santoro, R. C., Siragusa, S., … Castaman, G. (2023). IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy. Haemophilia : The Official Journal of the World Federation of Hemophilia, 29(1), 135–144. https://doi.org/10.1111/hae.14689

Chicago

Tagliaferri, Annarita, Angelo Claudio Molinari, Flora Peyvandi, Antonio Coppola, Francesco Demartis, Chiara Biasoli, Alessandra Borchiellini, et al. 2023. “IDEAL Study: A Real-World Assessment of Pattern of Use and Clinical Outcomes with Recombinant Coagulation Factor IX Albumin Fusion Protein (RIX-FP) in Patients with Haemophilia B in Italy.” Haemophilia : The Official Journal of the World Federation of Hemophilia 29 (1): 135–44. doi:10.1111/hae.14689.